弥漫大B细胞淋巴瘤患者自体干细胞移植后贝林妥欧单抗巩固治疗
该先导研究纳入14例弥漫大B细胞淋巴瘤或转化型滤泡性淋巴瘤患者,在BEAM方案自体干细胞移植后第42天开始接受1周期贝林妥欧单抗巩固治疗。结果显示治疗安全可耐受,5例发生1级细胞因子释放综合征,未观察到免疫效应细胞相关神经毒性综合征;移植后100天12例(86%)达完全缓解。
要点
- 14例弥漫大B细胞淋巴瘤或转化型滤泡性淋巴瘤患者自体移植后接受1周期贝林妥欧单抗巩固。
- 5例发生1级细胞因子释放综合征,无2级及以上细胞因子释放综合征,未观察到免疫效应细胞相关神经毒性综合征。
- 移植后100天12例(86%)达完全缓解,移植后1年7例(50%)维持完全缓解。
核心结论
- 该先导研究显示自体干细胞移植后贝林妥欧单抗巩固治疗安全且耐受良好。
- 作者认为需要采取提高CD8:CD4比值的策略并在更大样本随机试验中使用更多巩固周期,以确认自体移植后贝林妥欧单抗巩固治疗的疗效。
研究设计与样本
- 先导研究,纳入14例弥漫大B细胞淋巴瘤或转化型滤泡性淋巴瘤患者。
- 所有患者接受标准治疗的BEAM(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)预处理自体干细胞移植,移植后第42天开始1周期(4周持续输注)贝林妥欧单抗巩固治疗。
- 试验注册号:NCT03072771。
主要发现
- 全部14例入组患者完成BEAM自体干细胞移植和1周期移植后贝林妥欧单抗治疗。
- 5例发生1级细胞因子释放综合征,无2级及以上细胞因子释放综合征,未观察到免疫效应细胞相关神经毒性综合征。
- 移植后中位随访37个月(范围12-65个月),随访至移植后3年。
- 移植后100天(贝林妥欧单抗巩固后1个月),12例(86%)达完全缓解。
- 移植后1年,7例(50%)维持完全缓解,1例死于疾病进展;复发患者开始贝林妥欧单抗治疗前CD8:CD4 T细胞比值低于维持缓解患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为先导研究,样本量为14例。
- 作者指出需要采取提高CD8:CD4比值的策略并在更大样本随机试验中使用更多巩固周期,以确认疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who undergo autologous stem cell transplant (auto-SCT) are poor. Blinatumomab is a CD3/CD19 bispecific T-cell engager that directs cytotoxic T cells to CD19+ cells. Here, we performed a pilot study of blinatumomab consolidation after auto-SCT for 14 patients with DLBCL or transformed follicular lymphoma. All patients underwent standard-of-care auto-SCT with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning followed by 1 cycle (4 weeks continuous infusion) of blinatumomab consolidation starting at day 42 after auto-SCT. All 14 patients treated on study completed BEAM auto-SCT and 1 cycle of posttransplant blinatumomab. Five patients developed grade 1 cytokine release syndrome (CRS), with no grade 2 or higher CRS. Immune effector cell-associated neurotoxicity syndrome was not observed. Patients were followed up for 3 years after auto-SCT, with median follow-up of 37 (range, 12-65) months. One-hundred days after auto-SCT (1 month after blinatumomab consolidation), 12 patients (86%) had achieved complete remission. At 1 year after auto-SCT, 7 patients (50%) remained in CR, and 1 patient had died of progressive disease. Patients who relapsed had a lower CD8:CD4 T-cell ratio before starting blinatumomab than patients who remained in remission. This pilot study demonstrates blinatumomab consolidation after auto-SCT is safe and well tolerated. Strategies to increase the CD8:CD4 ratio and use additional cycles of consolidation in a larger randomized trial are needed to confirm the efficacy of consolidation with blinatumomab after auto-SCT. This trial was registered at www.clinicaltrials.gov as #NCT03072771.
引用
- Ghobadi A, Foley NC, Cohen J, et al. Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 37871306. doi:10.1182/bloodadvances.2023011130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。